If you’re aiming to build a balanced portfolio, having a few blue chip ASX shares in there could be a smart move.
But which blue chip ASX 200 shares should you buy? Two that are highly rated are listed below:
CSL Limited (ASX: CSL)
The first blue chip ASX 200 share to look at is biotechnology giant CSL.
CSL has a focus on rare and serious diseases through its CSL Behring business and influenza vaccines through its Seqirus business.
CSL Behring has a wide range of innovative therapies. These are used to treat immunodeficiencies, bleeding disorders, hereditary angioedema, Alpha 1 antitrypsin deficiency, and neurological disorders. Whereas Seqirus has a broad range of flu products meeting the needs of different populations around the world.
While COVID-19 has impacted its plasma collections and could weigh on its margins in the near term, the long term looks extremely positive. Especially given its burgeoning R&D pipeline and the increasing demand for plasma-based products.
This morning, analysts at Credit Suisse upgraded CSL’s shares to an outperform rating with a $315.00 price target.
Ramsay Health Care Limited (ASX: RHC)
Another ASX 200 blue chip share to look at is Ramsay Health Care. It is a leading private healthcare company with operations across the world.
While the pandemic hit Ramsay hard and led to a significant drop in elective surgeries, trading conditions have improved greatly in recent months. As a result, Ramsay looks well-placed to benefit from a backlog in surgeries in the near term and increased demand for healthcare services over the long term.
Macquarie is positive on the company. Earlier this week its analysts retained their outperform rating and $75.00 price target on Ramsay’s shares.
The broker has been pleased with recent activity trends and feels the company is well-positioned for growth over the long term.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
More reading
- Top brokers name 3 ASX shares to buy today
- Down 18%: Is the CSL (ASX:CSL) share price a buy?
- 8 ASX 200 shares rated as ‘outperform’ by brokers
- Is now the time to invest into the CSL (ASX:CSL) share price?
- How to counter the ASX 200’s Achilles heel
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post 2 blue chip ASX 200 shares that could be strong buys appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/3d3vKQs
Leave a Reply